<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2606">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749173</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1516101</org_study_id>
    <nct_id>NCT04749173</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study is a double-blind, randomized, placebo-controlled study designed to assess&#xD;
      the safety, tolerability and PK profile of single intramuscular doses of DWRX2003 in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>follow-up 42 days after dosing</time_frame>
    <description>Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: follow-up 42 days after dosing ]</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (96 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Ventrogluteal area: 48 mg/0.2 mL x 2 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (432 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deltoid area: 72 mg/0.3 mL x 2 sites&#xD;
Ventrogluteal area: 144 mg/0.6 mL x 2 sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (960 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deltoid area: 192 mg/0.8 mL x 2 sites&#xD;
Ventrogluteal area: 288 mg/1.2 mL x 2 sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWRX2003</intervention_name>
    <description>Drug: Placebo Intramuscularly injection at predefined injection sites</description>
    <arm_group_label>Cohort 1 (96 mg)</arm_group_label>
    <arm_group_label>Cohort 2 (432 mg)</arm_group_label>
    <arm_group_label>Cohort 3 (960 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults aged 19 or older and 55 or younger at the time of screening test&#xD;
&#xD;
          2. A person who weighs 55.0 kg or more and whose BMI (body mass index) is above 18.0 and&#xD;
             below 29.9;&#xD;
&#xD;
          3. A person who has listened to the detailed explanation of this clinical trial and fully&#xD;
             understood, decided to participate voluntarily, and agreed in writing before the&#xD;
             screening procedure.&#xD;
&#xD;
          4. A person who is eligible for this test when determining the person in charge of the&#xD;
             test (or co-researcher who has been commissioned) due to physical examination,&#xD;
             clinical laboratory examination, or examination.&#xD;
&#xD;
          5. A person who has been tested negative for Corona-19 virus (COVID-19) infection&#xD;
             conducted during a screening visit.&#xD;
&#xD;
          6. A person who has agreed to use medically acceptable contraception during the&#xD;
             pre-clinical trial period;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person with a history or medical condition that includes one or more of the&#xD;
             following diseases:&#xD;
&#xD;
               1. A person who is hypersensitive or has an history of overreaction to a clinical&#xD;
                  trial medication (or a component of a clinical trial medication) or emergency&#xD;
                  medication (epinephrine, dexamethasone, etc.)&#xD;
&#xD;
               2. hepatitis B (active hepatitis B or carrier), hepatitis C, human immunodeficiency&#xD;
                  virus (HIV), or syphilis infection (unless fully cured in case of hepatitis B&#xD;
                  virus history)&#xD;
&#xD;
               3. A person who is deemed clinically significant in determining the test manager (or&#xD;
                  a joint researcher) for the past or present history of asthma, rash, vascular&#xD;
                  edema, eczema, etc.&#xD;
&#xD;
               4. A person who has clinical significance, liver, kidney, nervous system,&#xD;
                  respiratory system, endocrine system, blood, tumor, cardiovascular, urinary&#xD;
                  system, mental system disease, or history&#xD;
&#xD;
               5. A person who has a history of malignant tumors in the past or present&#xD;
&#xD;
               6. A person who has a history of whole-body anti-infection that has been terminated&#xD;
                  within 28 days prior to the administration of clinical trial medication, or a&#xD;
                  history of systemic or local infection that requires hospitalization or&#xD;
                  intravenous administration within 6 months before clinical trial medication is&#xD;
                  administered.&#xD;
&#xD;
               7. A person who has undergone surgical intervention or surgery within 28 days prior&#xD;
                  to the administration of a clinical trial medication or is scheduled to undergo&#xD;
                  surgical procedures during the clinical trial period.&#xD;
&#xD;
               8. A person who has a clinically significant blood clotting disorder or tendency to&#xD;
                  hemorrhagic&#xD;
&#xD;
          2. A person who shows the following results in a screening test:&#xD;
&#xD;
             ﬁ A person whose blood level of AST (SGOT) and ALT (SGPT) exceeds twice the upper&#xD;
             limit of the reference range ﬁ A person whose blood treatment line level exceeds the&#xD;
             upper limit of the reference range or whose eGFR calculated by the Modification of&#xD;
             Diet in Rental Disase (MDR) formula is less than 90ml/min/1.73㎡ ﬁ A person who has&#xD;
             been found to be abnormal in the 12-lead ECG test ﬁ In the vital signs measured at the&#xD;
             left position after a rest for more than three minutes, a person who showed a figure&#xD;
             equivalent to systolic blood pressure of &quot;90 mmHg or &gt; 150 mmHg or extended blood&#xD;
             pressure of &quot;60 mmHg or &gt;100 mmHg.&quot; ﬁ A person who has tested positive for serum (RPR&#xD;
             Ab, anti-HIV (AIDS), HBs Ag, HCV Ab) ﬁ A person whose C-reactive protein (CRP) level&#xD;
             is 1.5 times higher than the upper limit of the reference range.&#xD;
&#xD;
             ﬁ In addition, a person who showed the results of a decision that the test manager (or&#xD;
             a commissioned joint researcher) is clinically significant;&#xD;
&#xD;
          3. A person who has a history of drug abuse or has tested positive for abuse in urine&#xD;
             drug testing&#xD;
&#xD;
          4. A person who participated in other clinical trials (including biological equivalence&#xD;
             tests) within six months prior to the administration of the clinical trial medication&#xD;
             (one test subject cannot participate in another cohort)&#xD;
&#xD;
          5. A person who has given full blood or blood donation within two months or within one&#xD;
             month before the administration of a clinical trial medication or received blood&#xD;
             transfusion within one month before the administration of a clinical trial medication.&#xD;
&#xD;
          6. A person who drinks continuously (21 units/week, 1 unit = 10 g of pure alcohol) within&#xD;
             three months prior to administration of clinical trial medication, or cannot drink&#xD;
             alcohol during hospitalization.&#xD;
&#xD;
          7. A person who smokes more than 10 cigarettes a day within one month prior to the&#xD;
             administration of a clinical trial medication or who is not allowed to smoke during&#xD;
             the hospitalization period.&#xD;
&#xD;
          8. A person who is not prohibited from eating anything other than food provided by the&#xD;
             clinical testing institution during his/her admission period;&#xD;
&#xD;
          9. A male person who has a child plan or plans to donate sperm during the period prior to&#xD;
             the clinical trial, or a female person who has a plan to conceive or breast-feed.&#xD;
&#xD;
         10. In addition to the above criteria, a person deemed inappropriate for the participation&#xD;
             of a clinical trial by the person in charge of testing (or a joint researcher who has&#xD;
             been delegated)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jang Hee Hong, Md, PhD</last_name>
    <phone>042-280-6910</phone>
    <email>boniii@cnu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungnam National university hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

